WebApr 23, 2024 · Tokyo-headquartered pharmaceutical firm Astellas has acquired Nanna, a biotech company based in Cambridge. Nanna is focused on addressing age-related diseases with high unmet medical need including mitochondria-related diseases. WebMar 24, 2024 · The acquisitions of Nanna, Audentes, Xyphos, Potenza, Quethera, Universal Cells, and Mitobridge are part of such an effort. ... Astellas also acquired Nanna in April 2024. By combining the Nanna' screening platform for compounds that act on intracellular targets with our mitochondrial biology capabilities, we aim to develop innovative therapies ...
Primary Focus: Mitochondria Astellas Pharma Inc.
WebApr 22, 2024 · Astellas, through its subsidiary in the United Kingdom, Astellas Pharma Europe Ltd., has purchased all of the issued share capital of Nanna through execution of a Share Purchase Agreement. Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters … http://pharmabiz.com/NewsDetails.aspx?aid=123602&sid=2 ウレシパチセ
ASTELLAS PHARMA EUROPE LTD. Active - Global Database
WebNanna and Mitobridge together comprise of the Mitobridge Division, a US- and UK-based research engine of Astellas reporting in to the Astellas Chief Scientific Officer, together … WebApr 21, 2024 · Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and … Astellas Announces Acquisition of Nanna Posted on April 21, 2024 April 21, 2024 … – Nanna’s unique screening platform has great potential to create novel programs, … WebAstellas, through its subsidiary in the United Kingdom, Astellas Pharma Europe Ltd., has purchased all of the issued share capital of Nanna through execution of a Share Purchase Agreement. Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas ... palette perdue gratuit